TCTR20170715001尚未招募未知
Comparative response evaluation of Cisplatin-Capecitabine with Cisplatin-5-Fluorouracil in advanced gastric carcinoma.
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1.Clinically diagnosed and histopathologically proved advanced gastric carcinoma (AJCC Stage IV).
- •2.At least one measurable lesion, no prior chemotherapy or radiotherapy.
- •3.Patients with Eastern Cooperative Oncology Group(ECOG) performance status up to 2.
- •4.Patients within the age limits of 18 to 70 years.
- •5.Presence of adequate renal, hepatic and cardiac function. Adequate renal function was defined as an estimated Creatinine Clearance Rate ≥60 ml/min using the Cockcroft and Gault formula. Adequate hepatic function was defined as Serum bilirubin ≤1.5 mg/dl, Serum transaminases ≤3 × upper normal limit or ≤5 × upper normal limit in cases of hepatic metastases).
排除标准
- •1.Pregnant or lactating women.
- •2.Serious concomitant medical illness including clinically significant cardiovascular disease, uncontrolled diabetes mellitus or hypertension.
- •3.Evidence of central nervous system metastases.
- •4.Major surgery of trauma in the previous four weeks.
研究者
相似试验
尚未招募
2 期
ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)ACTRN12608000061336Austin Health100
已完成
2 期
A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601)previously untreated non-small-cell lung ccancer, stage III (N2 positive)JPRN-UMIN000024816Okayama Lung Cancer Study Group (OLCSG)80
已完成
不适用
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancerMalignant neoplasm of ovaryOvarian CancerCancerISRCTN78953383Cancer Research UK (CRUK) (UK)
已完成
3 期
Randomized, comparative clinical study of cisplatin and docetaxel combination chemotherapy and mitomycin, vindesine and cisplatin (MVP) combination chemotherapy with concurrent thoracic radiation therapy for locally advanced unresectable non-small-cell lung cancer (OLCSG0007)inoperable locally advanced non-small-cell lung cancerJPRN-C000000085Okayama Lung Cancer Study Group (OLCSG)200
已完成
不适用
Feasibility study of the combination of cisplatin and docetaxel with concurrent thoracic radiotherapy for locally advanced resectable non-small cell lung cancer.ocally advanced resectable non-small-cell lung cancerJPRN-UMIN000008130Hamamatsu University School of Medicine3